Is it a Prudent Move to Retain MYGN Stock in Your Portfolio Now?

Myriad Genetics (MYGN) is strategically expanding its oncology companion diagnostics and launching new products, including Precise MRD and advanced prenatal screens, while benefiting from updated clinical guidelines for tests like Prolaris. Despite a history of earnings beats, MYGN shares have significantly underperformed, declining 74.5% over the past year. This underperformance is attributed to substantial macroeconomic headwinds, such as inflation and tariffs, coupled with an intensifying competitive landscape expected to pressure pricing and margins, contributing to a projected 1.9% decline in 2025 revenues.

Analysis

Myriad Genetics (MYGN) presents a stark contrast between its strategic initiatives and its market performance. The company is advancing its Oncology business through the development of its Precise MRD monitoring test, which demonstrated positive performance in a Phase 2 trial published in The Lancet Oncology, and the inclusion of its Prolaris test in updated NCCN guidelines. Furthermore, Myriad is expanding its portfolio with new offerings like the FirstGene prenatal screen, scheduled for full commercialization in 2026, and the Precise Tumor sequencing assay. Operationally, the company has delivered an average earnings surprise of 210% over the trailing four quarters. However, these positive developments are overshadowed by severe headwinds, reflected in a 74.5% share price decline over the past year, drastically underperforming the industry's 13.5% drop. The consensus estimate for 2025 revenue signals a 1.9% year-over-year decline, attributed to persistent inflation impacting labor and supply costs, and intensifying competition which is expected to erode pricing power and pressure margins.

Key Decisions for Investors

• Investors should weigh the long-term growth potential from Myriad's innovative pipeline, particularly the Precise MRD and FirstGene products, against the significant near-term risks of margin compression from competition and macroeconomic pressures.
• Monitor key catalysts for a potential turnaround, including the commercial adoption rates of new products and any evidence of market share stabilization or pricing power in future earnings reports.
• Given the severe stock underperformance and negative revenue outlook for 2025, a cautious stance is warranted; consider waiting for signs that the company can effectively manage costs and defend its pricing before committing new capital.